Hologic (NASDAQ:HOLX) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a report released on Saturday.

Several other research analysts have also commented on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 price target (up previously from $48.00) on shares of Hologic in a research report on Tuesday, January 9th. Bank of America raised Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price target on the stock in a research report on Thursday, January 4th. Evercore ISI assumed coverage on Hologic in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $50.00 price target on the stock. Cowen raised Hologic to a “buy” rating and set a $52.00 price target on the stock in a research report on Wednesday, December 20th. Finally, Goldman Sachs Group raised Hologic from a “buy” rating to a “conviction-buy” rating and lifted their price target for the stock from $45.00 to $50.00 in a research report on Friday, December 8th. One analyst has rated the stock with a sell rating, three have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $48.79.

Hologic (NASDAQ:HOLX) traded up $0.16 on Friday, reaching $43.71. The company’s stock had a trading volume of 3,060,000 shares, compared to its average volume of 2,747,611. The firm has a market capitalization of $12,050.00, a price-to-earnings ratio of 16.56, a price-to-earnings-growth ratio of 2.09 and a beta of 0.95. Hologic has a 52 week low of $35.76 and a 52 week high of $46.80. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.61 and a current ratio of 0.79.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 EPS for the quarter, topping the consensus estimate of $0.49 by $0.01. The company had revenue of $802.90 million for the quarter, compared to analyst estimates of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm’s revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 earnings per share. sell-side analysts predict that Hologic will post 2.15 earnings per share for the current fiscal year.

In other news, Director Elaine Ullian sold 9,282 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $40.50, for a total value of $375,921.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Karleen Marie Oberton sold 1,023 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $39.84, for a total value of $40,756.32. The disclosure for this sale can be found here. In the last three months, insiders sold 12,099 shares of company stock worth $487,223. Corporate insiders own 0.79% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Koch Industries Inc. boosted its stake in shares of Hologic by 15,554.1% in the second quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock valued at $1,125,000 after buying an additional 1,142,138 shares in the last quarter. Picton Mahoney Asset Management boosted its stake in shares of Hologic by 8.1% in the second quarter. Picton Mahoney Asset Management now owns 57,150 shares of the medical equipment provider’s stock valued at $2,593,000 after buying an additional 4,300 shares in the last quarter. Chevy Chase Trust Holdings Inc. boosted its stake in shares of Hologic by 1.4% in the third quarter. Chevy Chase Trust Holdings Inc. now owns 244,620 shares of the medical equipment provider’s stock valued at $8,975,000 after buying an additional 3,391 shares in the last quarter. Royce & Associates LP purchased a new stake in shares of Hologic in the second quarter valued at approximately $908,000. Finally, Cipher Capital LP boosted its stake in shares of Hologic by 57.9% in the third quarter. Cipher Capital LP now owns 117,673 shares of the medical equipment provider’s stock valued at $4,317,000 after buying an additional 43,146 shares in the last quarter. 97.58% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Hologic (HOLX) Lowered to “Sell” at BidaskClub” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://theolympiareport.com/2018/01/15/hologic-holx-lowered-to-sell-at-bidaskclub.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.